BeiGene Ltd. | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (31)

View All

Latest Posts

About This Stock More About This Stock
Week In Review: AriBio Sells China Rights To Alzheimer’s Candidate In $770 Million Deal
Article By: ChinaBio® Today
Saturday, March 30, 2024 2:40 PM EDT
South Korea’s AriBio out-licensed China rights for AR1001, an Alzheimer’s disease candidate, in an agreement worth up to $770 million. The company acquiring the asset asked to remain anonymous because of the competition for Alzheimer’s drugs.
In this article: BGNE, AVBP, WUXIF, NUVB Also: SPHDF
Read
Week In Review: Three Multinationals Plan Investments In Southeast Asia Facilities
Article By: ChinaBio® Today
Saturday, March 23, 2024 2:00 PM EDT
Shanghai WuXi Biologics has broken ground on a $1.4 billion facility in Singapore. Meanwhile, Novo Nordisk announced plans to invest $556 million to expand its Tianjin city production facility.
In this article: MRK, NVO, BGNE, WXXWY, IVBXF, WUXIF Also: NVS, CTLT
Read
3 Top Biotech Stocks Worth Adding To Your Portfolio In 2024
Article By: Zacks Investment Research
Sunday, January 7, 2024 9:00 AM EDT
Given the continuous need for innovative medical treatments, the biotech industry may be a haven despite its inherent volatility and an uncertain macroeconomic environment. Here are three top biotech stocks that will likely perform well in 2024.
In this article: REGN, SRPT, BGNE
Read
Week In Review: BeiGene Signs $1.3 Billion Deal For Preclinical CDK2 Inhibitor From Boston’s Ensem
Article By: ChinaBio® Today
Saturday, November 25, 2023 1:40 PM EDT
Beijing’s BeiGene acquired global rights to a preclinical novel cyclin-dependent kinase 2 (CDK2) inhibitor from Boston’s Ensem Therapeutics in a $1.3 billion agreement. Ensem will receive an upfront payment, plus milestones and royalties.
In this article: BGNE Also: AZN, WXXWY, CNTB
Read
Week In Review: China's Biopharmas Announce $2.5 Billion In Deals
Article By: ChinaBio® Today
Saturday, October 21, 2023 1:39 PM EDT
KBP Biosciences sold global rights for its hypertension candidate to Novo Nordisk in an agreement worth up to $1.3 billion. Also, EpimAb Bio sold the rights to use its Fabs-In-Tandem Immunoglobulin platform to Almirall in a $210 million agreement.
In this article: SRXXF, BGNE, WXXWY, ASPHF, NVO, LBTSF, TAK
Read
All Posts

Latest Tweets for $BGNE

No tweets yet!

PARTNER HEADLINES

$BGNE

Comments Status Updates
The World Has Turned Sunny
Marcy Brown • 11/10/2020 2:19:18 AM

I don't really understand why $BGNE was downrated. The news was positive.

1 to 1 of 1 comments